|Podcasts|December 3, 2021
Pharmacy Focus: Psychedelic Pharmacy - Episode 2
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Advertisement
In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Role of the Pharmacist in the Management of Psychosis in Parkinson’s Disease
2
High-Fat Dairy Consumption Linked to Decreased Risk of Dementia
3
RSV Hospitalization Associated With Persistent Symptoms and Reduced Quality of Life in Adults
4
Study Links Specific Air Pollution Components to Increased Depression Risk in Older Adults
5